SELECT (cardiovascular outcomes in obesity, no diabetes) The single most important data point published on semaglutide outside diabetes was the SELECT trial, Lincoff et al., NEJM 2023, PMID 37962078
Effect of Subcutaneous Semaglutide vs
India, China, and Brazil: The Generic Inflection Point India represents one of the most significant emerging frontiers for GLP-1 uptake
For this reason, doctors may recommend pairing GLP-1 receptor agonist treatment with a high-protein diet and strength training to maintain muscle mass
Indias situation is different from the United States, as its enormous portion size is normal, whereas Indian diets are traditionally more grain and vegetable-based, and shared family meals